Literature DB >> 21323605

Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias.

Jean-Daniel Abraham1, Sophie Calvayrac-Pawlowski, Sandra Cobo, Nicolas Salvetat, Guillaume Vicat, Laurence Molina, Jacques Touchon, Bernard-François Michel, Franck Molina, Jean-Michel Verdier, Jeannette Fareh, Chantal Mourton-Gilles.   

Abstract

Using proteomic approach in cerebrospinal fluid (CSF) we identified pigment epithelium-derived factor (PEDF) and Haptoglobin (Hp) as putative markers that could discriminate between AD and other dementias. ELISA assays were developed to measure the levels of PEDF and Hp in CSF from patients with AD (AD, n=27), non-AD (NAD, n=30) and in non-demented patients (ND, n=27). The combined assessment of PEDF, Hp and Tau levels, using Iterative Marginal Optimization, improved the differential diagnosis of AD, especially in patients with moderate to severe dementia (p<0.002). This pilot study highlights the probable different contribution of oxidative mechanisms in dementia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21323605     DOI: 10.3109/1354750X.2010.536995

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  8 in total

1.  Haptoglobin genotype modulates the relationships of glycaemic control with cognitive function in elderly individuals with type 2 diabetes.

Authors:  Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Andrew Levy; Derek Leroith; Michal S Beeri
Journal:  Diabetologia       Date:  2015-01-28       Impact factor: 10.122

2.  Variations in the cerebrospinal fluid proteome following traumatic brain injury and subarachnoid hemorrhage.

Authors:  David E Connor; Ganta V Chaitanya; Prashant Chittiboina; Paul McCarthy; L Keith Scott; Lisa Schrott; Alireza Minagar; Anil Nanda; J Steven Alexander
Journal:  Pathophysiology       Date:  2017-05-13

Review 3.  Cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Xiaojing Sui; Jianjun Liu; Xifei Yang
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

4.  Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians.

Authors:  Pedro Rosa-Neto; Ging-Yuek Hsiung; Mario Masellis
Journal:  Alzheimers Res Ther       Date:  2013-11-25       Impact factor: 6.982

5.  Clear differences in cerebrospinal fluid proteome between women with chronic widespread pain and healthy women - a multivariate explorative cross-sectional study.

Authors:  Patrik Olausson; Bijar Ghafouri; Emmanuel Bäckryd; Björn Gerdle
Journal:  J Pain Res       Date:  2017-03-13       Impact factor: 3.133

6.  Pigment Epithelium-Derived Factor Plays a Role in Alzheimer's Disease by Negatively Regulating Aβ42.

Authors:  Mao Huang; Weiwei Qi; Shuhuan Fang; Ping Jiang; Cong Yang; Yousheng Mo; Chang Dong; Yan Li; Jun Zhong; Weibin Cai; Zhonghan Yang; Ti Zhou; Qi Wang; Xia Yang; Guoquan Gao
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

7.  Cerebrospinal Aβ11-x and 17-x levels as indicators of mild cognitive impairment and patients' stratification in Alzheimer's disease.

Authors:  J-D Abraham; S Promé; N Salvetat; L Rubrecht; S Cobo; E du Paty; P Galéa; E Mathieu-Dupas; S Ranaldi; C Caillava; G-A Crémer; F Rieunier; P Robert; F Molina; D Laune; F Checler; J Fareh
Journal:  Transl Psychiatry       Date:  2013-07-16       Impact factor: 6.222

8.  Proteomic analysis and comparison of intra‑ and extracranial cerebral atherosclerosis responses to hyperlipidemia in rabbits.

Authors:  Zhi-Lan Tu; Bo Yu; Dong-Ya Huang; Rajeev Ojha; Shu-Kui Zhou; He-Di An; Rong Liu; Cui Du; Nan Shen; Jian-Hui Fu; Shuang-Xing Hou
Journal:  Mol Med Rep       Date:  2017-06-28       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.